Rigel Pharmaceuticals Inc (RIGL)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Raul R. Rodriguez
Employees:
158

Rigel Pharmaceuticals, Inc. is a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The company focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Its current product development programs include Fostamatinib Oral SYK Inhibitor and R348 Topical Ophthalmic JAK/SYK Inhibitor. Rigel Pharmaceuticals was founded by Donald G. Payan, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Data derived from most recent annual or quarterly report
Market Cap 548.429 Million Shares Outstanding170.85 Million Avg 30-day Volume 944.713 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-2.15
Price to Revenue31.4986 Debt to Equity0.0 EBITDA-33.382 Million
Price to Book Value2.6665 Operating Margin-358.9646 Enterprise Value217.946 Million
Current Ratio7.516 EPS Growth0.721 Quick Ratio6.953
1 Yr BETA 52-week High/Low 5.5 / 2.36 Profit Margin-363.205
Operating Cash Flow Growth-45.7097 Altman Z-Score13.1882 Free Cash Flow to Firm -55.319 Million
View SEC Filings from RIGL instead.

View recent insider trading info

Funds Holding RIGL (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding RIGL BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

LYONS GARY A

  • Director
55,000 2021-05-19 1

MOOS WALTER H

  • Director
57,222 2021-05-19 1

GOODWIN BRADFORD S

  • Director
65,000 2021-05-19 1

KATKIN KEITH

  • Director
55,000 2021-05-19 1

LAPOINTE ANTHONY GREGG

  • Director
55,000 2021-05-19 1

WASMAN JANE

  • Director
55,000 2021-05-19 1

HANNAH ALISON L.

  • Director
13,750 2021-05-19 3

KOTZIN BRIAN L.

  • Director
55,000 2021-05-19 1

RODRIGUEZ RAUL R CEO, PRESIDENT

  • Officer
  • Director
162,500 2021-04-01 2

VANCE DOLLY EVP CORP. AFFAIRS, G.C., SECT.

  • Officer
37,500 2021-04-01 2

SCHORNO DEAN L EVP &CHIEF FINANCIAL OFFICER

  • Officer
50,000 2021-04-01 2

DUMMER WOLFGANG EVP & CMO

  • Officer
0 2021-01-27 1

SANTOS DAVID A EVP, CHIEF COMMERCIAL OFFICER

  • Officer
0 2021-01-27 1

CABATUAN NELSON VP,FINANCE & PRINC.ACCTG. OFF.

  • Officer
0 2020-05-14 0

MASUDA ESTEBAN SR. VP RESEARCH

  • Officer
0 2019-11-18 0

LASAGA JOSEPH SR.VP BUS.DEV.ALLIANCE MGMT.

  • Officer
0 2019-11-18 0

MAYER ELDON C. III EVP & CHIEF COMMERCIAL OFFICER

  • Officer
0 2019-11-18 0

DULIEGE ANNE-MARIE EVP & CHIEF MEDICAL OFFICER

  • Officer
0 2019-03-20 0

MARKEL STACY EVP HUMAN RESOURCES

  • Officer
0 2019-03-20 0

RINGROSE PETER S

  • Director
0 2018-05-17 0

MAYNARD RYAN D EVP & CFO

  • Officer
0 2017-11-03 0

PAYAN DONALD G EVP, PRES. DISCOVERY&RESEARCH

  • Officer
  • Director
53,031 2016-08-30 0

SHERWIN STEPHEN A

  • Director
0 2016-05-11 0

GROSSBARD ELLIOTT B EVP, CMO

  • Officer
0 2016-01-26 0

GOWER JAMES M CEO & BOARD CHAIRMAN

  • Officer
  • Director
0 2014-02-27 0

BVF PARTNERS L P/IL

BIOTECHNOLOGY VALUE FUND L P

BVF INC/IL

LAMPERT MARK N

BIOTECHNOLOGY VALUE FUND II LP

BVF INVESTMENTS LLC

  • 10% Owner
  • SEE EXPLANATION OF RESPONSES SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
No longer subject to file 2013-11-19 0

RENTON HOLLINGS

  • Director
0 2013-05-15 0

BVF PARTNERS L P/IL

BIOTECHNOLOGY VALUE FUND L P

BIOTECHNOLOGY VALUE FUND II LP

BVF INVESTMENTS LLC

INVESTMENT 10 LLC

BVF INC/IL

LAMPERT MARK N

  • 10% Owner
  • SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
9,697,997 2013-05-01 0

FLYNN JAMES E

DEERFIELD CAPITAL LP

DEERFIELD SPECIAL SITUATIONS FUND, L.P.

DEERFIELD PARTNERS, LP

DEERFIELD MANAGEMENT CO /NY

DEERFIELD SPECIAL SITUATIONS FUND INTERNATIONAL LTD

DEERFIELD INTERNATIONAL LTD

  • 10% Owner
  • POSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUP
No longer subject to file 2011-05-26 0

DELEAGE JEAN

  • Director
0 2010-05-28 0

COOPER ROBIN D G SR. V.P. PHARMACEUTICAL SCS.

  • Officer
0 2008-01-31 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
RIGEL PHARMACEUTICALS INC RIGL 2021-10-26 22:15:03 UTC -0.3598 0.4298 4100000
RIGEL PHARMACEUTICALS INC RIGL 2021-10-26 21:45:03 UTC -0.3598 0.4298 4100000
RIGEL PHARMACEUTICALS INC RIGL 2021-10-26 21:15:03 UTC -0.3598 0.4298 4100000
RIGEL PHARMACEUTICALS INC RIGL 2021-10-26 20:45:03 UTC -0.3598 0.4298 4100000
RIGEL PHARMACEUTICALS INC RIGL 2021-10-26 20:15:03 UTC -0.3598 0.4298 4100000
RIGEL PHARMACEUTICALS INC RIGL 2021-10-26 19:45:03 UTC -0.3598 0.4298 4100000
RIGEL PHARMACEUTICALS INC RIGL 2021-10-26 19:15:03 UTC -0.3598 0.4298 4100000
RIGEL PHARMACEUTICALS INC RIGL 2021-10-26 18:45:03 UTC -0.3598 0.4298 4100000
RIGEL PHARMACEUTICALS INC RIGL 2021-10-26 18:15:03 UTC -0.3598 0.4298 4100000
RIGEL PHARMACEUTICALS INC RIGL 2021-10-26 17:45:03 UTC -0.3598 0.4298 4100000
RIGEL PHARMACEUTICALS INC RIGL 2021-10-26 17:15:03 UTC -0.3598 0.4298 4100000
RIGEL PHARMACEUTICALS INC RIGL 2021-10-26 16:45:04 UTC -0.3598 0.4298 4100000
RIGEL PHARMACEUTICALS INC RIGL 2021-10-26 16:15:03 UTC -0.3598 0.4298 4100000
RIGEL PHARMACEUTICALS INC RIGL 2021-10-26 15:45:03 UTC -0.3598 0.4298 4100000
RIGEL PHARMACEUTICALS INC RIGL 2021-10-26 15:15:03 UTC -0.3598 0.4298 4100000
RIGEL PHARMACEUTICALS INC RIGL 2021-10-26 14:45:03 UTC -0.1919 0.2619 4100000
RIGEL PHARMACEUTICALS INC RIGL 2021-10-26 14:15:05 UTC -0.1919 0.2619 4100000
RIGEL PHARMACEUTICALS INC RIGL 2021-10-26 13:45:03 UTC -0.1919 0.2619 4100000
RIGEL PHARMACEUTICALS INC RIGL 2021-10-26 13:15:03 UTC -0.1919 0.2619 4100000
RIGEL PHARMACEUTICALS INC RIGL 2021-10-26 12:45:03 UTC -0.1919 0.2619 4100000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
RUSSELL INVESTMENT FUNDS- U.S. Small Cap Equity Fund RIGL -18359.0 shares, $-79678.06 2021-06-30 N-PORT
RUSSELL INVESTMENT CO- U.S. Small Cap Equity Fund RIGL -109897.0 shares, $-439588.0 2021-07-31 N-PORT

Elevate your investments